Combined Effects of Transcutaneous Electrical Diaphragmatic Stimulation With ACBT'S in Copd
1 other identifier
interventional
50
1 country
1
Brief Summary
The combined effects of transcutaneous electrical diaphragmatic stimulation (TEDS) and active cycle of breathing techniques (ACBTs) in patients with chronic obstructive pulmonary disease (COPD) conducted as a randomized controlled trial at Gulab Devi Hospital, the study involved 50 participants aged 40 to 60 with mild to moderate COPD. Participants were divided into two groups, one receiving both TEDS and ACBT, and the other receiving only ACBT. Over 12 weeks, improvements in lung function, oxygen saturation, exercise capacity, and quality of life were measured using spirometry, pulse oximetry, the 6-minute walk test, and the St. George's Respiratory Questionnaire. Both groups showed significant improvement, but the group receiving ACBT alone showed a slightly higher mean rank in some outcomes. The study concludes that while both interventions are beneficial, ACBT alone may offer more consistent improvements. It recommends including respiratory muscle assessments and combining interventions with education and exercise in future research.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 28, 2025
CompletedFirst Submitted
Initial submission to the registry
July 3, 2025
CompletedFirst Posted
Study publicly available on registry
July 23, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 28, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
November 10, 2025
CompletedJuly 23, 2025
July 1, 2025
5 months
July 3, 2025
July 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Forced Expiratory Volume in 1 second (FEV1) using Spirometry
FEV1 measures the volume of air that can be forcibly exhaled in one second. It is a key indicator of airway obstruction and lung function in COPD patients.
12 weeks
Forced Vital Capacity (FVC) using Spirometry
FVC measures the total amount of air that can be forcibly exhaled after taking the deepest breath possible.
12 weeks
FEV1/FVC Ratio using Spirometry
using Spirometry
12 weeks
St. George's Respiratory Questionnaire (SGRQ)
Assesses health-related quality of life specific to respiratory diseases
baseline and at 12 weeks post intervention
6-Minute Walk Test (6MWT)
Assesses functional exercise capacity.
Baseline and at 12 weeks post-intervention
Secondary Outcomes (1)
Oxygen Saturation after 6-Minute Walk Test (6MWT) via Pulse Oximetry
Baseline and at 12 weeks post-intervention
Study Arms (2)
TEDS + ACBT
EXPERIMENTALParticipants receive transcutaneous electrical diaphragmatic stimulation (TEDS) along with active cycle of breathing techniques (ACBTs) daily for 12 weeks.
ACBT only
ACTIVE COMPARATORParticipants receive only active cycle of breathing techniques (ACBTs) daily for 12 weeks.
Interventions
TEDS was applied using surface electrodes placed over the diaphragm region. The stimulation protocol was set at 50 Hz frequency, 300 μs pulse width, with 6 seconds of stimulation followed by 5 seconds of rest, daily for 12 weeks. It was combined with ACBT sessions.
ACBT sessions included breathing control, thoracic expansion exercises, and forced expiration techniques (huffing). Sessions were performed daily for 12 weeks to aid in secretion clearance and improve lung function.
Eligibility Criteria
You may qualify if:
- COPD (Mild to Moderate)
- Age: 40-60 years of both genders
- Productive cough for more than 2 months
- Oxygen saturation without Oxygen supply \> 88%
You may not qualify if:
- Uncontrolled hypertension
- Cardiac diseases
- Active smokers
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Arjumand
Lahore, Punjab Province, 40100, Pakistan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Arjumand Bano, MS-CPPT
Riphah International University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 3, 2025
First Posted
July 23, 2025
Study Start
May 28, 2025
Primary Completion
October 28, 2025
Study Completion
November 10, 2025
Last Updated
July 23, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share